Pharmacist Moms Group^™

Experts discuss how atebimetinib and adjusted chemotherapy schedules enhance tolerability and treatment duration for pancreatic cancer patients.

Joe Saseen explains how persistent cholesterol myths undermine care and why emerging oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors could expand access to intensive LDL-C lowering.

In this episode, the panel reflects on how this program can help pharmacists strengthen their approach to tardive dyskinesia (TD) recognition and management.

Explore effective strategies for managing side effects in patients, emphasizing communication, monitoring, and education for optimal health outcomes.

In this episode, the panel discusses how pharmacists and the broader care team can support adherence and strengthen communication when patients start deutetrabenazine or valbenazine.

Explore the real-world challenges and strategies for patient adherence in treatment, emphasizing education and shared decision-making for better outcomes.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Pharmacists adapt to new CDC guidelines, emphasizing pneumococcal vaccination for adults 50+, enhancing patient screening and vaccination efficiency.

Experts discuss groundbreaking data on pancreatic cancer treatment, revealing a 64% survival rate and its potential to transform patient care and outcomes.